NIH-funded research R01 grant

Choosing Immune Suppression in Kidney Transplantation for Better Long-Term Graft Health

Official title: Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity 2 (CISTEM2)

Funded at Rutgers Biomedical and Health Sciences · NIH-11416281 · Data updated 2026-11-12

A patient-friendly look at a study aimed at optimizing immune-suppressing medicines after kidney transplant to improve graft survival and reduce complications.

More Renal Transplantation research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionRutgers Biomedical and Health Sciences
NIH-funded
Lab location1 site (Newark, UNITED STATES)
Project startFebruary 1, 2025
Project endJanuary 31, 2029
Funding year2026
Award (this year)$644,764
NIH project number5R01DK139339-03
Project IDNIH-11416281 on NIH RePORTER

Who could benefit from this research

Could help

Adults who have undergone kidney transplantation and are navigating long-term immune-suppressant therapy.

Less likely to help

Patients not yet receiving kidney transplants or those not involved in post-transplant care may not directly benefit.

What this research studies

This project uses large health data from kidney transplant patients to create a richer, more actionable picture of how different immune-suppressing medicines affect long-term graft health and safety. It builds on past work and adds more detailed clinical information and lab results to support better, shared decision-making between patients and clinicians. Researchers will link national transplant data with medical records and pharmacy information to study long-term outcomes like infections, cancer, diabetes, rejection, and survival. A patient-facing web tool will help providers and patients choose regimens that balance effectiveness with risks. The goal is to improve personalized care and outcomes for people living with kidney transplants.

Why it matters

Potential benefit: If successful, patients could benefit from more tailored immune-suppressant choices that improve graft longevity and reduce serious complications.

How similar studies have gone: Building on prior CISTEM work, this project aims to enhance evidence and tools for decision-making, with a track record suggesting meaningful progress is possible.

Where this research is happening

  • Rutgers Biomedical and Health Sciences
    Newark, United States
    Active

Researchers

  • Principal investigator: Dharnidharka, Vikas R. — Rutgers Biomedical and Health Sciences
  • Study coordinator: Dharnidharka, Vikas R.

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.